You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康辰藥業(603590.SH):擬將相關募投項目變更為“年產500kg抗腫瘤原料藥生產基地建設項目”
格隆匯 04-21 21:50

格隆匯4月21日丨康辰藥業(603590.SH)公佈,因公司終止“注射用鹽酸洛拉曲克”(“迪奧”)的臨牀試驗及後續研發,擬將募投項目“鹽酸洛拉曲克原料藥產能建設項目”變更為“年產500kg抗腫瘤原料藥生產基地建設項目”,為公司其他在研國家一類抗腫瘤新藥提供原料藥。

“鹽酸洛拉曲克原料藥產能建設項目”擬投入募集資金8000萬元,截至2020年3月31日,已投入4433.64萬元,其中募集資金3560.72萬元,自有資金872.92萬元,該項目募集資金餘額4654.17萬元(含理財利息淨收入214.89萬元)。此次變更後,原募投項目“鹽酸洛拉曲克原料藥產能建設項目”已投入建成的廠房及在建工程,將繼續用於公司其他在研品種原料藥生產。新募投項目“年產500kg抗腫瘤原料藥生產基地建設項目”計劃投資總額為9800萬元,該項目已投入4433.64萬元,剩餘建設期內計劃投入5366.36萬元,募投資金不足部分由公司通過銀行貸款或自有資金等方式解決。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account